Trial Profile
Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 15 Nov 2018 Results assessing drug-drug interaction between nintenib and pirfenidone for the treatment of idiopathic pulmonary fibrosis, published in the European Respiratory Journal.
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.